Introduction
============

Malignant lymphoma represents a group of malignant tumors originating in the lymphatic hematopoietic system. Malignant lymphoma can be classified as T-cell lymphoma, B-cell lymphoma, or natural killer cell lymphoma depending on the cells of origin. According to its pathology, clinical features, and prognosis, malignant lymphoma can be further classified into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). NHL includes a group of highly heterogeneous lymphoproliferative disorders, and its incidence in People's Republic of China is far higher than that of HL. Moreover, NHL can be further classified as highly aggressive, aggressive, or indolent lymphoma according to the natural course of the disease. Although aggressive NHL develops rapidly, \~62.8%--65.1% of patients show long-term disease-free survival.[@b1-ott-10-5727] However, as nearly half of all patients eventually show disease progression or develop refractory symptoms after chemotherapy,[@b2-ott-10-5727] it is critical to accurately classify patients according to risk in the early stages and to adjust the treatment strategy based on the results of risk assessment.

The International Prognostic Index (IPI) has been widely used in clinical diagnosis and treatment as an important prognostic indicator of aggressive lymphoma.[@b3-ott-10-5727] Nonetheless, the application of IPI has been challenged with the development of molecularly targeted therapeutics, such as rituximab. Despite the development of a revised IPI,[@b4-ott-10-5727] neither of these measures includes tumor cell surface molecular markers. In recent years, several studies have found that whole-genome expression profiles can provide predictive molecular biology-based information for lymphoma patients; however, these special tests are expensive, and they have not been routinely implemented in clinical practice. Positron emission tomography (PET)/computed tomography (CT) imaging is increasingly being applied to lymphoma, and this new method of detection has shown robust advantages in the diagnosis, staging, and prognostic evaluation of aggressive NHL. Compared with clinical indicators such as age, physical fitness status score, clinical stage, and lactate dehydrogenase levels, PET/CT can be dynamically evaluated according to the patient's response to chemotherapy during treatment. Recent studies have shown that interim PET/CT therapeutic evaluation is an independent prognostic factor that is superior to the aforementioned criteria after chemotherapy. However, when evaluating PET/CT treatment effects, correctly interpreting the imaging results is challenging. Visual judgment, Δ maximum SUX (SUVmax), and quantitative analysis are currently the main methods of PET/CT interpretation. Visual interpretation includes the Deauville criteria (5-point method) and the International Harmonization Project (IHP) criteria. As previous studies have suggested that interpretation of Deauville criteria is more accurate for aggressive lymphoma PET/CT evaluation, the use of these criteria has been recommended by National Comprehensive Cancer Network guidelines for the therapeutic evaluation of diffuse large B-cell lymphoma and HL.[@b5-ott-10-5727] However, several researchers have reported[@b6-ott-10-5727]--[@b9-ott-10-5727] that interim PET/CT findings using the Deauville criteria failed to demonstrate clinical utility in the evaluation of diffuse large B-cell lymphoma prognosis and treatment efficacy. Therefore, the accuracy of visual interpretation has yet to be fully demonstrated. In the present study, a meta-analysis and systematic review were performed to evaluate the predictive value of interim PET/CT visual interpretation for the prognosis of aggressive NHL.

Methods
=======

Search strategy
---------------

We searched the literature for studies published in PubMed, Embase, Web of Science, and the Cochrane Library through May 2017 reporting the use of visual evaluation mid-chemotherapy to examine the prognosis of lymphoma.

Search keywords included "positron emission tomography/computerized tomography" OR "PET/CT" AND "lymphoma" AND "visual" AND "overall survival" OR "progression-free survival" OR "prognostic". The literature search was restricted to English-language publications. To avoid omissions, both editorials and reviews were used as search sources, and we retrieved additional possibly valuable documents from the articles. Letters and summaries of meetings were excluded based on the absence of important raw data. When the effective data included in the literature were not reported or when data published in different studies overlapped, we contacted the author to confirm the appropriate data. If the results of a study reported by different authors were clearly from the same analysis, only the latest information and the most complete study were used.

Inclusion criteria
------------------

1.  Histopathological confirmation of aggressive lymphoma[@b10-ott-10-5727]

2.  Interim evaluation including visual evaluation of PET/CT images

3.  Relevant survival data, such as overall survival (OS) and progression-free survival (PFS)

4.  Publicly available studies

Exclusion criteria
------------------

1.  Indolent lymphoma

2.  Review articles, meeting summaries, letters

3.  PET/CT evaluation not including a visual method

4.  The results of PET/CT visual interpretation not analyzed for survival, as indicated by the absence of relevant prognostic indicators, such as the hazard ratio (HR), death/survival, survival, and survival curves

5.  Incomplete follow-up information, with a loss rate greater than 20%, and reporting of results with less than 2 years of follow-up

Literature quality evaluation
-----------------------------

The included articles were evaluated as a non-randomized controlled cohort study performed in accordance with the Newcastle-Ottawa quality assessment scale (NOS) for quality assessment.[@b11-ott-10-5727] The NOS scale includes the following: 1) selection (representativeness of exposed queues, selection of non-exposed queues, determination of exposure, no subject had an outcome event prior to the study initiation, full marks represent 4 points); 2) comparability (whether the study controls for the most important factors, whether the study controls for other important confounding factors, full marks represent 2 points); and 3) outcome (assessment of outcome events, whether the follow-up is sufficient, completeness of follow-up, full marks represent 3 points). Full marks according to NOS are represented by 9 points; scores of 0--4 indicate low-quality research, and scores of 5--9 indicate high-quality research.

Data extraction
---------------

We extracted the following data: 1) the first author's name and the date of publication; 2) baseline data for the study population, including sample size, sample origin, age, and others; 3) PET measurement parameters; and 4) OS rate, PFS rate (HR), 95% confidence interval (CI), and corresponding *p*-value. If the HR and the 95% CI could not be obtained from the original manuscript or corresponding author, the observed total number of deaths and the sample size for each group were extracted to calculate the HR. If the survival curve in the study was reported, the corresponding survival period of each point was obtained from the graph, and the HR was calculated using the method reported by Tierney.[@b12-ott-10-5727] Data extraction was performed independently by 2 researchers according to pre-established criteria. The 2 researchers independently searched the literature and selected articles for inclusion. Final decisions concerning whether to incorporate a study were made by discussion or by consulting a third party. When the data in the literature were incomplete, we contacted the corresponding author of the study as often as possible to obtain the relevant information.

Statistical analysis
--------------------

HR combination analysis was performed under the assumption of clinical homogeneity. The 95% CI represents the statistical effect. The heterogeneity of each study was analyzed by the *χ*^2^ test. With *p*\<0.1 as the significance level, heterogeneity was expressed as an *I*^2^ value. When the *I*^2^ value is close to zero, heterogeneity can be attributed to chance; less than 25% indicates mild heterogeneity, 25%--50% indicates moderate heterogeneity, and more than 50% indicates a high degree of heterogeneity among studies.[@b13-ott-10-5727] When heterogeneity was present, a random effects model (DerSimonian-Laird method) was used; otherwise, a fixed effects model (Mantel--Haenszel test) was employed. We utilized a funnel map[@b14-ott-10-5727] and Egger's test[@b15-ott-10-5727] to determine whether there was publication bias in the included studies. If the test indicated the presence of publication bias, we applied the "Decline Method" to estimate the number of articles that were potentially missing and corrected for the combined effect values.[@b16-ott-10-5727] Finally, by sequentially removing each of the included studies, subsequent sensitivity analysis was performed by means of effect-quantity combination to evaluate the robustness and reliability of each study. In general, an HR \>1.0 was considered to indicate a poor survival rate for patients in the PET(+) visual interpretation group; an HR \<1.0 in the PET(−) visual interpretation group was associated with poor survival. A lack of overlap of the HR (CI) with 1 suggested that the results of visual interpretation had statistical value for survival prediction. All *p*-values were calculated with 2-sided tests.

Effect-quantity pooling, heterogeneity testing, sensitivity analysis, and bias testing were analyzed using the meta-package in R (ver.3.2.3; a language and environment for statistical computing; <https://www.R-project.org/>).[@b17-ott-10-5727]

Results
=======

Results of literature screening
-------------------------------

After screening for inclusion and investigation criteria, 11 studies were ultimately included ([Table 1](#t1-ott-10-5727){ref-type="table"}).[@b7-ott-10-5727],[@b18-ott-10-5727]--[@b27-ott-10-5727]

Literature quality evaluation
-----------------------------

All of the 11 eligible studies were based on pathologic diagnosis, and the lymphoma subtype, sex, age, and treatment of the patients were described. The baseline conditions of each group were comparable. The basic features of the eligible studies are shown in [Table 1](#t1-ott-10-5727){ref-type="table"}. The quality of the 11 eligible studies was assessed in strict accordance with the NOS. The scores ranged from 7 to 9 points, suggesting that the methodological quality level of each eligible study was sufficiently high ([Table 2](#t2-ott-10-5727){ref-type="table"}).

Meta-analysis results
---------------------

We performed meta-analysis of 2 end points (PFS and OS). Eight and nine studies analyzed the effects of visual interpretation of interim PET/CT evaluation on the PFS and OS, respectively, of patients with aggressive lymphoma.

### HR of PFS and subgroup analysis

The quantitative results of overall heterogeneity testing (Q test; tau[@b2-ott-10-5727]=0; *p*=0.6945) and the *I* [@b2-ott-10-5727] index test (*I*^2^=0.0%) suggested that there was no significant heterogeneity among the studies. Therefore, a fixed effects model was used for the analysis, and the overall HR was found to be 2.93 (95% CI: 2.93--3.90, *p*\<0.0001). The PFS of interim PET/CT-positive patients was low based on the vision method, and the difference was statistically significant.

In subgroup analysis with interpretation criteria as the classification method ([Figure 1](#f1-ott-10-5727){ref-type="fig"}), quantitative results of tests for the Deauville criteria using the Q test (tau[@b2-ott-10-5727]=0; *p*=0.6273) and the *I*^2^ index test (*I*^2^=0.0%) indicated no significant heterogeneity among the studies. Thus, a fixed effects model was employed for the analysis; the HR was 2.91 (95% CI: 1.68--5.04). The PFS of positive patients, as judged by the Deauville 5-point criteria, was low, with a statistically significant difference.

The quantitative results for the IHP group using the Q (tau[@b2-ott-10-5727]=0; *p*=0.8211) and *I*^2^ index (*I*^2^=0.0%) tests suggested that no significant heterogeneity was present, and a fixed effects model was used for the analysis; the HR was 2.92 (95% CI: 1.81--4.70). The PFS of positive patients, as determined by the IHP method, was low. The difference was statistically significant.

Quantitative testing for the no standard interpretation group using the Q test (tau[@b2-ott-10-5727]=0.3084; *p*=0.0867) and *I*^2^ index test (*I*^2^=59.1%) indicated the presence of heterogeneity among the studies. Therefore, a random effects model was used for the analysis, with an HR of 3.47 (95% CI: 1.53--7.87). The results showed that the PFS of positive patients, as judged by each method with no standard interpretation, was low. The difference was statistically significant.

In subgroup analysis with the number of chemotherapy cycles before PET imaging as the classification method ([Figure 2](#f2-ott-10-5727){ref-type="fig"}), the quantitative results for the group with an average number of chemotherapy cycles before PET of less than 3 (Q test \[tau[@b2-ott-10-5727]=0; *p*=0.7938\] and *I*^2^ index test \[*I*^2^=0.0%\]) suggested no significant heterogeneity. Therefore, we employed a fixed effects model for the analysis; the HR was 2.89 (95% CI: 1.75--4.78). The PFS of positive patients who had less than 3 chemotherapy cycles according to Deauville 5-point criteria and IHP criteria was low, and the difference was statistically significant.

For the group with an average number of chemotherapy cycles before PET greater than 3 (Q test \[tau[@b2-ott-10-5727]=0; *p*=0.6835\] and *I*^2^ index test \[*I*^2^=0.0%\]), the quantitative results suggested that no significant heterogeneity was present among the studies. Accordingly, a fixed effects model was used for the analysis; the HR was 2.94 (95% CI: 1.75--4.82). The results showed that the PFS of the positive patients who had more than 3 chemotherapy cycles, as judged by the Deauville 5-point and IHP methods, was low. The difference was statistically significant.

### HR of OS and subgroup analysis

The quantitative results of overall heterogeneity testing (Q test \[tau[@b2-ott-10-5727]=0.087; *p*=0.1912\] and *I*^2^ index test \[*I*^2^=28.5%\]) indicated no significant heterogeneity in the studies. The overall HR using a fixed effects model was 2.55 (95% CI: 1.76--3.68, *p*\<0.0001). The results showed that the OS of interim PET/CT-positive patients was low according to the vision method, and the difference was statistically significant.

In subgroup analysis using interpretation criteria as the classification method ([Figure 3](#f3-ott-10-5727){ref-type="fig"}), the quantitative results for the Deauville group (Q test \[tau[@b2-ott-10-5727]=0.3808; *p*=0.1078\] and *I*^2^ index test \[*I*^2^=61.3%\]) suggested moderate heterogeneity among the studies. Thus, a random effects model was used; the HR was 1.99 (95% CI: 0.67--5.93). The results showed that the OS of Deauville 5-point method-positive patients was low, though statistical significance was not reached.

The quantitative results for the IHP group (Q test \[tau[@b2-ott-10-5727]=0; *p*=0.5734\] and *I*^2^ index test \[*I*^2^=0.0%\]) revealed no significant heterogeneity, and the fixed effects model showed an HR of 2.29 (95% CI: 1.38--3.79). According to the results, the OS of IHP method-positive patients was low, and the difference was statistically significant.

For the no standard interpretation group, the quantitative results (Q test \[tau[@b2-ott-10-5727]=0.3184; *p*=0.0938\] and *I*^2^ index test \[*I*^2^=53.1%\]) indicated heterogeneity among the studies, and the HR was 3.63 based on a random effects model (95% CI: 1.66--7.90). A low OS was found for patients positive according to each method with no standard interpretation. The difference was statistically significant.

In subgroup analysis with the number of chemotherapy cycles before PET as the classification method ([Figure 4](#f4-ott-10-5727){ref-type="fig"}), the quantitative results for the group with the average number of chemotherapy cycles before PET of fewer than 3 (Q test \[tau[@b2-ott-10-5727]=0.0162; *p*=0.3454\] and *I*^2^ index test \[*I*^2^=5.9%\]) suggested no significant heterogeneity. Therefore, a fixed effects model was used for the analysis, with an HR of 1.69 (95% CI: 0.96--2.95). The OS of positive patients whose average number of chemotherapy cycles was fewer than 3, as judged by the Deauville 5-point and IHP methods, was low, with no statistical significance.

The quantitative results for the group with the average number of chemotherapy cycles before PET greater than 3 (Q test \[tau[@b2-ott-10-5727]=0; *p*=0.5269\] and *I*^2^ index test \[*I*^2^=0.0%\] indicated a lack of significant heterogeneity among the studies, and the HR was 2.74 according to the fixed effects model used for analysis (95% CI: 1.53--4.89). The results showed that the OS of positive patients whose average number of chemotherapy cycles was greater than 3, as determined by the Deauville 5-point and IHP criteria, was low. The difference was statistically significant.

### Eligible study publication bias

1.  The funnel plots ([Figure 5A](#f5-ott-10-5727){ref-type="fig"}) included in [Figure 1](#f1-ott-10-5727){ref-type="fig"} are basically symmetrical. Egger's test ([Figure 5B](#f5-ott-10-5727){ref-type="fig"}) showed a bias of 2.69, *p*=0.0938. There was no significant publication bias.

2.  The funnel plots ([Figure 6A](#f6-ott-10-5727){ref-type="fig"}) presented in [Figure 2](#f2-ott-10-5727){ref-type="fig"} are essentially symmetrical. Egger's testing ([Figure 6B](#f6-ott-10-5727){ref-type="fig"}) revealed a bias of −1.02, *p*=0.6629, with no significant publication bias.

3.  Essentially symmetrical funnel plots ([Figure 7A](#f7-ott-10-5727){ref-type="fig"}) are shown in [Figure 3](#f3-ott-10-5727){ref-type="fig"}. Egger's testing ([Figure 7B](#f7-ott-10-5727){ref-type="fig"}) showed a bias of 1.89, *p*=0.1114. There was no significant publication bias.

4.  [Figure 4](#f4-ott-10-5727){ref-type="fig"} displays basically symmetrical funnel plots ([Figure 8A](#f8-ott-10-5727){ref-type="fig"}). Egger's testing ([Figure 8B](#f8-ott-10-5727){ref-type="fig"}) showed a bias of 1.78, *p*=0.5165, with no significant publication bias.

### Sensitivity analysis

We performed sensitivity analysis of eight studies with PFS as an end point and nine studies with OS as an end point. After excluding single clinical trials, the total analysis of the included studies showed that patient prognosis could be predicted, suggesting that heterogeneity between studies was not caused by a single study with variable quality. No single study had a significant effect on the overall analysis, and the overall effect exhibited good stability.

Discussion
==========

Fludeoxyglucose (FDG)-PET/CT imaging has strongly contributed to systematic staging and efficacy evaluation of lymphoma. In 2007, the International Coordination Project formally introduced PET/CT imaging into the efficacy evaluation of lymphoma.[@b28-ott-10-5727],[@b29-ott-10-5727] FDG-PET/CT is currently recommended for staging and efficacy evaluation of FDG-high-affinity lymphoma and is mainly used to image the metabolic uptake of tumor tissues to evaluate the efficacy of treatment. Overall, the guiding effect of this approach on the value of long-term prognosis and treatment decision-making is significantly better than the previous method used by the International Working Group, which was adopted in 1999 and relied on measuring the size of the lesion based on CT imaging.[@b30-ott-10-5727] There are 3 important time points for PET/CT in the evaluation of staging and curative effects in aggressive lymphoma: 1) baseline PET/CT before chemotherapy; 2) interim efficacy evaluation; and 3) confirmation of curative effect after chemotherapy. Among these, the value of mid-term efficacy evaluation has been a significant focus of academic research. Although there are many prognostic factors and evaluation systems that help to determine overall prognosis, it is often difficult to determine individual treatment options accordingly. Early screening of refractory or rapidly relapsing patients can help in the implementation of early recovery programs (such as chemotherapy, transplantation, or new targeted drugs) to improve outcomes. By contrast, early identification of patients with a good prognosis can allow for the treatment intensity to be adjusted, thereby reducing long-term toxicity or the occurrence of a second primary tumor. It has been reported that interim PET/CT can accurately predict the treatment response of patients with lymphoma as well as patients early in treatment who are at risk of failure, and it can predict PFS.[@b21-ott-10-5727],[@b26-ott-10-5727],[@b31-ott-10-5727] In a prospective clinical study of 90 patients with diffuse large B-cell lymphoma, PET/CT imaging of positive patients after 2 cycles of chemotherapy suggested a poor prognosis, and the results were independent of the treatment regimen and age-adjusted IPI.[@b24-ott-10-5727] Similarly, PET/CT imaging after 4 cycles of chemotherapy also showed a good predictive value.[@b32-ott-10-5727] Regardless, there are many studies suggesting that interim PET/CT cannot accurately predict the prognosis of patients[@b7-ott-10-5727],[@b33-ott-10-5727],[@b34-ott-10-5727] and that changing the treatment strategy based on the outcome of interim PET/CT analysis does not lead to survival benefits.[@b34-ott-10-5727] In the rituximab era, the clinical trial prediction value of interim PET/CT has not been good, and several scholars believe that the results of accurate histopathological examination and genetic testing can more accurately guide changes in chemotherapy protocols.[@b18-ott-10-5727] In the present study, a number of related homogeneous research studies were merged and systematically reviewed, with the goal of providing a higher level of evidence-based medical support for the interim PET/CT evaluation strategy and its predictive value in aggressive NHL.

How to determine the interim PET/CT visual interpretation method
----------------------------------------------------------------

Visual interpretation is designed to assess treatment response using the simplest method. We used a non-standardized method, IHP criteria, and Deauville criteria for interpretation of the studies included in our analysis. The non-standardized method has been developed and used by various researchers, though it is not officially recognized. Through heterogeneity testing of relevant studies, we found that the non-standardized method results in large heterogeneity between different centers or different observers.[@b23-ott-10-5727] IHP criteria represent a purely visual evaluation method. This classification method states that residual lesions greater than 2 cm be referred to the mediastinal pool and that lesions less than 2 cm be compared with the surrounding background. There are studies[@b8-ott-10-5727],[@b35-ott-10-5727] suggesting that the predictive value of chemotherapy efficacy evaluation after 2--4 cycles of immunochemotherapy is poor; the main manifestation of this is that a low positive predictive value is obtained using IHP criteria. The Deauville criteria represent a relatively new visual interpretation methodology, with a 5-point method for analysis. In contrast with the IHP standard method, comparison of liver FDG uptake is included, which improves the accuracy of interpretation. In addition, the Deauville criteria do not include a method to absorb the surrounding environment and classify and compare cases according to tumor size, thus reducing errors caused by different backgrounds of the residual mass. Furthermore, the diagnostic threshold can be adjusted based on the scores, and the Deauville criteria can further improve diagnostic efficiency and interobserver consistency. Nonetheless, in this study, negative results were obtained when using the Deauville criteria for interim PET/CT meta-analysis with OS as the end point. This was due to the high heterogeneity of the study by Mamot et al,[@b27-ott-10-5727] which applied an ultra-early interim PET/CT time point. Although IHP and Deauville criteria are being used by an increasing number of centers due to their simplicity and consistency with different observers, OS according to Deauville's criteria prediction in lymphoma patient should be considered with caution. More research should be performed to explore the Deauville criteria for diagnostic thresholds.

Selection of interim PET/CT examination time point
--------------------------------------------------

In the subgroup with an average number of chemotherapy cycles fewer than 3 before interim PET/CT examination, the OS of positive and negative patients, as judged by the visual method, was not statistically significant. By contrast, the OS and PFS of positive and negative patients, as based on the visual method, were low in the subgroup with an average number of chemotherapy cycles greater than 3 before interim PET/CT examination. One of the reasons for the poor predictive efficiency of early PET/CT may be an increase in the false-positive rate, as inflammatory reactions caused by chemotherapeutic drugs after tumor regression increase FDG uptake. In addition, in a study using the IPI as a stratification factor,[@b19-ott-10-5727] visual interpretation of ultra-early interim PET/CT (evaluated immediately after 1--2 cycles of chemotherapy) did not appear to fully reflect the patients' response to treatment. In that study, several interim PET-positive patients with high IPI scores were ultimately cured because the 2--3 cycles of chemotherapy were inadequate for patients with a high tumor burden and the assessment was too early to evaluate the effectiveness of the intervention. Many clinical trials have employed ΔSUVmax for semi-quantitative interpretation, and this measure for early PET/CT can generate more information about ΔSUV uptake changes than the Deauville 5-point method. Thus, using ΔSUVmax in such patients may be a better choice.[@b26-ott-10-5727] However, there is no uniform standard for ΔSUVmax interpretation; indeed, most clinical studies use different diagnostic thresholds, and the sample sizes are small. Moreover, when the baseline SUVmax is less than 10, ΔSUVmax analysis is prone to false-negative results.[@b8-ott-10-5727] In addition, ΔSUVmax calculation requires access to baseline PET data, which is not always available in high-risk patients who need immediate interventional chemotherapy. Based on these considerations, we propose that the positive predictive value of using the visual approach for early interim evaluation (after 1--2 cycles of chemotherapy) is low, and we recommend that evaluation be performed after at least after 3 cycles of chemotherapy. Multi-parameter stratification analysis (such as combining IPI, molecular typing, and others) may help to improve the predictive value, but additional larger clinical trials are needed.

Conclusion
==========

In summary, IHP and Deauville criteria are commonly applied for PET/CT visual evaluation. The interim PET/CT visual method after 3--4 cycles of chemotherapy can accurately assess disease prognosis, but whether this outcome can be used as a basis for changing treatment strategy remains to be confirmed in a large prospective clinical trial.
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###### 

Patient baseline characteristics

  Eligible studies                  Year   Patient number   Research design   Average age (years)   Pathology                    Chemotherapy regimen   Number of chemotherapy cycles before interim PET   Visual method criteria                                                   Ann arbor staging (i, ii/iii, iv)
  --------------------------------- ------ ---------------- ----------------- --------------------- ---------------------------- ---------------------- -------------------------------------------------- ------------------------------------------------------------------------ -----------------------------------
  Zinzani et al[@b18-ott-10-5727]   2011   91               Prospect          54                    DLBCL, PMLBCL                R-CHOP                 2                                                  IHP                                                                      30/61
  Yoo et al[@b20-ott-10-5727]       2011   155              Review            N/A                   DLBCL                        R-CHOP                 2--4                                               No standard interpretation[\#](#tfn1-ott-10-5727){ref-type="table-fn"}   68/87
  Yang et al[@b19-ott-10-5727]      2011   159              Review            61                    DLBCL                        R-CHOP                 3--4                                               IHP                                                                      94/67
  Spaepen et al[@b21-ott-10-5727]   2002   70               Prospect          50                    DLBCL, ALCL, MCL, BL, PTCL   CHOP                   3--4                                               No standard interpretation[\#](#tfn1-ott-10-5727){ref-type="table-fn"}   22/49
  Safar et al[@b22-ott-10-5727]     2012   112              Prospect          59                    DLBCL                        R-CHOP, R-ACVBP        2                                                  No standard interpretation[\#](#tfn1-ott-10-5727){ref-type="table-fn"}   21/91
  Nols et al[@b23-ott-10-5727]      2014   73               Review            60                    DLBCL                        R-CHOP, R-ACVBP        3--4                                               Deauville                                                                23/50
  Haioun et al[@b24-ott-10-5727]    2005   90               Prospect          53                    DLBCL, PTCL                  CHOP/ACVBP/ACE ± R     2                                                  No standard interpretation[\#](#tfn1-ott-10-5727){ref-type="table-fn"}   8/82
  Cashen et al[@b25-ott-10-5727]    2011   50               Prospect          58                    DLBCL                        R-CHOP                 2--3                                               IHP                                                                      0/50
  Pregno et al[@b7-ott-10-5727]     2012   88               Prospect          55                    DLBCL                        R-CHOP                 2--4                                               Deauville                                                                29/59
  Itti et al[@b26-ott-10-5727]      2013   114              Review            56                    DLBCL                        R-CHOP, R-ACVBP        2                                                  IHP                                                                      20/94
  Mamot et al[@b27-ott-10-5727]     2015   125              Prospect          59                    DLBCL                        R-CHOP                 2                                                  Deauville                                                                64/74

**Note:**

Mainly based on non-physiological-FDG tissue uptake as an interpretation reference.

**Abbreviations:** DLBCL, diffuse large B-cell lymphoma; PMLBCL, primary mediastinal large B-cell lymphoma; IHP, International Harmonization Project; ALCL, anaplastic large cell lymphoma; CHOP, cyclophosphamide, hydroxydaunomycin, oncovin (vincristine), prednisone; MCL, mantle cell lymphoma; BL, Burkitt's lymphoma; PTCL, peripheral T-cell lymphoma; R, rituximab; ACVBP, adriamycin (doxorubicin), cyclophosphamide, vindesine, bleomycin, prednisone; ACE, adriamycin, cyclophosphamide, etoposide; FDG, fludeoxyglucose; PET, positron emission tomography; N/A, not available.

###### 

Methodological quality evaluation (NOS)

  Eligible studies                  Selection                                      Comparability                                  Outcome                                        Score                                                                                                                                                                                                                                        
  --------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ------------------------------------------------ ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---
  Zinzani et al[@b18-ott-10-5727]   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*\*](#tfn4-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   9
  Yoo et al[@b20-ott-10-5727]       [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   8
  Yang et al[@b19-ott-10-5727]      [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   8
  Spaepen et al[@b21-ott-10-5727]   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   8
  Safar et al[@b22-ott-10-5727]     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*\*](#tfn4-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   9
  Nols et al[@b23-ott-10-5727]      [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   8
  Haioun et al[@b24-ott-10-5727]    [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*\*](#tfn4-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   --                                             8
  Cashen et al[@b25-ott-10-5727]    [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   --                                             [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   7
  Pregno et al[@b7-ott-10-5727]     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   --                                             [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   7
  Itti et al[@b26-ott-10-5727]      [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   --                                             [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   7
  Mamot et al[@b27-ott-10-5727]     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}     [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   [\*](#tfn5-ott-10-5727){ref-type="table-fn"}   8

**Notes:** The full score of comparability is 2. The score of the remaining items is 1 point.

indicates 2 point;

Indicates 1 point; -- indicates no points.

**Abbreviation:** NOS, Newcastle-Ottawa quality assessment scale.

[^1]: These authors contributed equally to this work
